Based on the timeframe used by CMS to identify the original list of 10 drugs (Medicare Part D gross expenditures from June 1, 2022 to May 31, 2023), it is possible that some of these drugs will only make the list only for a short while. Stelara (#27 on 2021 Medicare spend), Xarelto, Januvia and Entresto have biosimilar or generic competition pending, though there is uncertainty regarding the exact timing of entry of competitors. Xarelto and Januvia generics won’t be available by August 2024, but may be in 2025 and 2026, respectively. This means their maximum fair prices will only apply for one to two years. Another product, Enbrel, is a special case. An Enbrel-referenced biosimilar, Erelzi was approved in 2016, but its U.S. launch has been delayed by litigation until 2029.